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Summary: Therapy of renal anaemia in haemodialysis patients with chronic renal failure by application of
recombinant human erythropoietin leads to an increase of the haematocrit. Rejuvenation of the erythrocyte
population results in a decrease of the median density (D50), an increase of cell age-dependent enzyme activities,
such as aspartate aminotransferase, and elevated concentrations of purine nucleotides in the erythrocytes.
After density gradient separation of erythrocyte populations into cell age-dependent fractions, the concentra-
tions of adenosine-S'-triphosphate, guanosine-5'-triphosphate and guanosine-5'-diphosphate were be found
to be elevated by 25 —100% in all cell fractions from haemodialysis patients, compared with a healthy control
group. Therapy of haemodialysis patients with recombinant human erythropoietin leads to further increase
(65%) of ATP in the younger (low density) cells, but not in the older (high density) cells. The elevated
concentrations of ATP and total adenine nucleotides during recombinant human erythropoietin therapy
possibly result in improved deformability of erythrocytes. The data point to an enhancement of the proportion
of younger erythrocytes, but not to an improvement of the reduced life span of erythrocytes of haemodialysis
patients during therapy with recombinant human erythropoietin.
Introduction f r . uspan of erythrocytes of uraemic patients may be an
Anaemia in patients with chronic renal failure (renal increased activity of plasma neuraminidase (6). Fur-
anaemia) is partly caused by a reduction of erythro- thermore, there are several reports of oxygen damage
poietin synthesis. This results in diminished produc- of erythrocytes in uraemic patients due to an imbal-
tion of erythrocytes in these patients. Additionally, ance between prooxidative reactions and antioxida-
the life span of erythrocytes of uraemic patients is tive defence mechanisms (7).
reduced (1—4). The life span of erythrocytes is deter- .
. , - - . * u v u· u · · u F°r the past few years it has been possible to treatmined by their energy metabolism, which is given by , · , _ « · · · f u· ^ u, - 7 · * A r™ j renal anaemia by administration of recombinant hu-the flux rate through glycolysis and ATP production . . ,- . - ° >T r. , ·,,·/. man erythropoietin (1). The enhancement ot haema-via this pathway (5). One cause of a decreased life . ^ . ' . . -tocnt during recombinant human erythropoietin ther-
apy due to stimulation of erythropoiesis in these pa-
i) Enzymes tients leads to an improved oxygen supply and, there-
Aspartate aminotransferase (EC 2.6.1.1) fore, to an improvement of the conditions required
Hexokinase (EC 2.7.1.1) for many metabolic functions. Data on the improve-
Aldolase (EC 4.1.2.13) * r * · * u r j · u· * u
Pyruvate kinase (EC 2.7.1.40) ment °f Protem metabolism during recombinant hu-
Glucose-6-phosphate dehydrogenase (EC 1.1.1.49) man erythropoietin therapy have already been re-
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ported (8). Stimulation of erythrocyte formation dur-
ing recombinant human erythropoietin administra-
tion is accompanied by a significant decrease in the
proportion of median density (D50) of erythrocytes,
and by increased cell age-dependent enzyme1) activi-
ties in all erythrocy te fractions (9 — 11).
The aim of this study was to answer the following
questions.
1) Can the increased deformability of erythrocytes
following recombinant human erythropoietin therapy,
as measured in rheological studies (12, 13), be inter-
preted on the basis of elevated intraerythrocytic en-
ergy-rich purine nucleotides?
2) Is recombinant human erythropoietin therapy of
haemodialysis patients accompanied by an increase
in the life span of erythrocytes, based on purine nu-
cleotide measurements?
3) Do the erythrocytes of haemodialysis patients ex-
hibit changes in purine nucleotide pattern during long
term (1 year) therapy with recombinant human eryth-
ropoietin?
Patients and Methods
Eighteen healthy subjects (8 male and 10 female subjects), aged
from 21 to 56 years, were compared as a control group with
14 haemodialysis patients (4 male and 10 female patients) aged
from 26 to 76 years [Hb 81.5 + 5.1 g/1]. The uraemic patients
were haemodialysed three times per week for 4—5 hours. The
recombinant human erythropoietin dosage was chosen to pro-
duce an enhancement of haemoglobin concentrations up to 100
g/1, followed by maintenance of this value. Recombinant human
erythropoietin was a gift of Boehringer Mannheim GmbH,
Germany.
Blood samples (3 — 5 ml venous blood) from haemodialysis
patients were drawn in the morning before haemodialysis ses-
sions. Informed consent was obtained according to standards
of the Ethic Committee of the Department of Medicine of the
Freie Universit t Berlin. Blood samples from control subjects
were also drawn in the morning. Preparations for the different
assays were immediately carried out.
Erythrocyte suspensions for density gradient centrifugation were
prepared from heparinized blood. Blood (10 ml) was centri-
fuged for 10 min at 4 °C and 800 g. Plasma was removed and
erythrocytes were resuspended in N-2-hydroxyethylpiperazine-
N'-l-ethanesulphonic acid (HEPES) buffer (133 mmol/1 NaCl,
4.5 mmol/1 KC1, 10 mmol/1 HEPES, pH 7.4). The suspension
was filtered through α-cellulose/microcrystalline cellulose
(2 + 1, by weight) according to Beutler et al. (14) to eliminate
leukocytes. The haematocrit of filtered blood was adjusted to
about 0.30 with HEPES buffer (4 °C).
Percoll gradient separation (11): 2ml of filtered blood were
layered on top of 12 ml of a continuous Percoll density gradient
solution and centrifuged for 10 min at 10 000 g in a Sorvall
centrifuge at 4 °C. The density gradient was obtained by cen-
trifugation of a 50% Percoll solution in HEPES buffer for 10
min at 10000 g and 4 °C. Separated erythrocytes were collected
from the bottom of the vials in 24 fractions (500 μΐ) using a
pump and a glass capillary. Fraction 1, the highest density
fraction, was located at the bottom; fraction 24, the lowest
density fraction, was located at top of the vial. Densities of the
fractions were determined with the help of colour markers.
Each fraction was washed three times with 1000 μΐ HEPES
buffer. Centrifugation was carried out hi Eppendorf vials and
an Eppendorf centrifuge. Erythrocyte pellets were kept deep
frozen at — 20 °C until determination of enzyme activities.
Samples for purine nucleotide analysis were immediately ex-
tracted.
Extraction procedure of nucleotides: Fractions were deprotein-
ized with ice cold 60 g/1 perchloric acid, centrifuged for 10 min
at 1200 g and neutralized with K2CO3. After a second centrif-
ugation the supernatant was stored at —20 °C. Ten or twenty
microlitres of supernatant were analysed by HPLC (15, 16).
HPLC equipment of Waters Assoc., Milford, MA; USA: M510
pump, Rheodyne injector, variable wavelength detector (ad-
justed to 254 nm), 740 DATA Module and a 640-system con-
troller; columns: 5 μιη Novapak C18 cartridges (100 mm
χ 8 mm i. d.) with a RCM compression system. Purine nucleo-
tides were determined with an isocratic ion pair reversed phase
HPLC system (15, 16). The eluent contained 10 mmol/1
NH4H2PO4, 2 mmol/1 PIC reagent A and acetonitrile, volume
fraction 0.2. Flow rate: 2 ml/min.
Activities of aspartate aminotransferrase1) were determined
after thawing and suspending erythrocyte pellets in 300 μΐ aqua
bidest using the GOT test kit No. 3329 (Merck Darmstadt,
Germany). Haemoglobin concentration was measured with the
Merckotest kit No. 3317 (Merck Darmstadt, Germany).
Results
Erythrocytes from patients with chronic renal failure
undergoing haemodialysis exhibit increased enzyme
activities in all cell fractions of the Percoll gradient
in comparison with erythrocytes from healthy sub-
jects. The most prominent differences between enzyme
activities of patients and healthy subjects were found
in cell fractions 15 — 24, which contain erythrocytes
with low densities. These erythrocytes were termed
young erythrocytes, as indicated by the cell age-de-
pendent aspartate aminotransferase activity (17) (fig.
1). During recombinant human erythropoietin ther-
apy, catalytic activity concentrations of aspartate ami-
notransferase increase, reaching a maximum one week
after the start of therapy. However, these activities
decrease to the initial value during the first year of
therapy.
In contrast to restoration of enzyme activity after the
first year of recombinant human erythropoietin ther-
apy, median densities stay constantly low, demon-
strating a continuous generation of young erythro-
cytes during the time of recombinant human eryth-
ropoietin administration: haemodialysis patients
D50 = 1.0548 ± 0.0002 kg/1 (pcontrol < 0.05); haemo-
dialysis patients after one year of recombinant human
erythropoietin therapy D50 = 1.0543 ± 0.0009 kg/1,
(Pcontroi < 0.05); healthy control group D50 = 1.0740
± 0.0002 kg/1. Like the aspartate aminotransferase
activities, the ATP concentrations in erythrocytes of
haemodialysis patients are increased in comparison
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Aspartate aminotransferase activities in erythrocyte
fractions of Percoll density gradient. High density frac-
tions 1 — 15 are old cell fractions, low density fractions
15 — 24 are young cell fractions. Comparison of hae-
modialysis patients before ( +), during 1 week (a) and
during 1 year (X) of recombinant human erythropoietin
therapy with values of a healthy control group (O).
Significance (Student's t):
* ρ (before therapy) < 0.05
+ ρ (control) < 0.05
with healthy subjects (tab. 1). Furthermore, the ATP
content in young erythrocyte fractions is significantly
higher during recombinant human erythropoietin
treatment than before recombinant human erythro-
poietin administration. The ATP content of the "old"
cells (fractions 1 — 15) after the first year of recom-
binant human erythropoietin therapy shows no dif-
ferences compared with the value before the start of
therapy. On the other hand, concentrations of ADP
in old fractions and AMP in young and old eryth-
rocyte fractions of recombinant human erythropoietin
treated patients show significantly higher values than
those of the patients before recombinant human
erythropoietin therapy (tab. 1). GTP and GDP con-
centrations are increased in erythrocytes of haemo-
dialysis patients compared with a healthy control
group (fig. 2), but show no significant changes be-
tween haemodialysis patients before and after recom-








Fig. 2. Guanosine nucleotide content in erythrocytes (young
and old cell fractions) of haemodialysis patients before
(Π) and after one year of therapy with recombinant
human erythropoietin (^) compared with a healthy
control group (0).
Significance (Student's t):
-f ρ (control) < 0.05.
Discussion
Cell densities of erythrocytes increase with increasing
cell age for nearly 120 days, the physiological life span
of human erythrocytes. Therefore, the median density
of the erythrocyte population has been suggested as
an indicator for changes of cell age (14). Thus, the
Tab. 1. Purine nucleotide concentrations in erythrocytes of haemodialysis (HD) patients before and after one year of recombinant
human erythropoietin (rhEPO) therapy compared with a healthy control group.










































4.38 ± 1.34 +
4.02 ±1.71 + +
0.05
2.23 ± 0.63





1.63 + 0.50 +
0.77 ± 0.32 +
0.05
0.67 ± 0.16 -f +





7.29 ± 2.68 '++**
3.82 + 1.75 +
0.01
2.26 ± 0.49
1.87 + 0.51 +*
0.05
1.16 ± 0.31 ++**
0.52 + 0.20 +*
0.01
1.61 ± 0.61 +
0.98 + 0.54 +
0.01
0.72 ± 0.31 + +
0.38 + 0.20 + +
0.01
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decrease of median density (D50) of erythrocytes in
patients with chronic renal failure, undergoing hae-
modialysis and treatment with recombinant human
erythropoietin can be interpreted on the basis of an
accelerated generation of young erythrocytes (9 — 11).
The activities of many enzymes of erythrocytes are
cell age-dependent. In particular, the activities of hex-
okinase, aldolase, pyruvate kinase and aspartate ami-
notransferase decrease during cell aging (18, 19). As-
partate aminotransferase in this study and in earlier
studies of our group served as a marker enzyme for
the age of erythrocytes. Erythrocyte density fractions
of haemodialysis patients showed significantly higher
aspartate aminotransferase activities (11) as an
expression of reduced life span, which was demon-
strated by means of 51Cr experiments (3). In addition
to an elevated aspartate aminotransferase1) activitiy,
erythrocytes of haemodialysis patients also exhibit
elevated pyruvate kinase1), hexokinase1) and glucose-
6-phosphate dehydrogenase1) activities (20).
After the first year of administration of recombinant
human erythropoietin to patients, the enzyme activity
decreases rapidly to values found in the cell popula-
tion of patients without recombinant human eryth-
ropoietin therapy; this indicates that the toxic damage
of the erythrocytes due to uraemia, persists during
recombinant human erythropoietin therapy.
We found increased ATP and GTP concentrations in
erythrocytes of haemodialysis patients. The increased
erythrocytic ATP concentrations in uraemic patients
are in agreement with previously published data (21 —
24). To our knowledge, the observation of elevated
GTP concentrations, however, is a new finding. In-
creased ATP concentrations in uraemic erythrocytes
may be due, on the one hand to a decreased loss of
ATP during ageing of erythrocytes (25) and, on the
other hand to changes in enzyme activities in path-
ways of nucleotide metabolism. Generally speaking,
increases or decreases of ATP concentrations of eryth-
rocytes reflect differences between production and
consumption of this energy rich compound. In eryth-
rocytes, generation of ATP only depends upon the
flux rate through glycolysis, regulated by the enzyme
activities of this pathway, especially by the activity of
the key enzymes, hexokinase and phosphofructoki-
nase. Hexokinase activity in erythrocytes is strongly
cell age-dependent (17, 26). This might be the reason
for the decreased ATP concentrations in erythrocytes
in dependence upon density in all three groups of
patients or healthy subjects. On the other hand, the
ATP consuming processes, especially transport proc-
esses through plasma membranes and processes con-
nected with cell shape changes mediated by cytoske-
leton activities, influence the topical ATP level. From
a comparison between immature red blood cells —
the reticulocytes — and mature red blood cells — the
erythrocytes — is known that reticulocytes exhibit a
75-fold higher rate of ATP consumption (27) and a
3-fold higher ATP concentration (28) in comparison
with erythrocytes. Therefore, one may suggest that
"old" erythrocytes with lower ATP content are prob-
ably characterized by a decreased ATP consumption
rate under quasi steady state conditions when com-
pared with younger cells. This may be in agreement
with the disturbances of electrolyte concentrations in
red cells with ageing, especially with the decrease of
intracellular K+ and Mg2* and an increase of intra-
cellular Na+ concentration (29).
Increased ATP concentrations in erythrocytes of
uraemic patients seem to be connected with decreased
cell age; in addition, they are possibly associated with
the adaptation of cells to the higher demand for the
transport of electrolytes and organic compounds
which are accumulated in the plasma. Furthermore,
changes of enzyme activities in pathways of nucleotide
metabolism in the erythrocytes of haemodialysis pa-
tients have been described by Hefti et al. (3), who
showed an enhanced purine nucleotide synthesis via
salvage pathways in erythrocytes of uraemic patients.
The possible influence of higher phosphate concen-
trations on the erythrocyte glycolytic rate has also
been discussed (20, 20, 31).
The increase of the ATP concentration after the long
term presence of erythropoietin can be explained as
rejuvenation of the erythrocyte population. There is
no doubt that in the presence of recombinant human
erythropoietin the life span of red cells in haemodi-
alysis patients remains the same (or slightly increased),
compared with cells in haemodialysis patients before
recombinant human erythropoietin treatment. Never-
theless, the causes of ATP enhancement in erythro-
cytes during recombinant human erythropoietin treat-
ment are unknown. Tracer-kinetic experiments are
necessary to obtain more information on the balance
between ATP formation and consumption in eryth-
rocytes in haemodialysis patients treated with recom-
binant human erythropoietin. This might answer the
question of which part of ATP turnover is changed
during the recombinant human erythropoietin treat-
ment — the ATP production via glycolysis or the ATP
consuming processes.
The increased ATP concentration together with in-
creased aspartate aminotransferase activities in "old"
erythrocytes from haemodialysis patients treated with
recombinant human erythropoietin, compared with
"old" erythrocytes before recombinant human eryth-
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ropoietin therapy (fig. 1) may indicate an unchanged
reduced life span of erythrocytes during recombinant
human erythropoietin therapy. This finding is in
agreement with data published in I.e. (12). These
authors measured an unchanged reduced life span of
erythrocytes before and 6 months after recombinant
human erythropoietin therapy.
The increased nucleotide concentrations of erythro-
cytes of haemodialysis patients treated with recom-
binant human erythropoietin can explain the partial
restoration of the decreased erythrocyte deformability
in haemodialysis patients (12, 13). Several authors
have clearly demonstrated the decrease of deforma-
bility of erythrocytes in patients with chronic renal
failure (32). The reasons for the beneficial recombi-
nant human erythropoietin effect on the rheological
properties of the blood (12, 13) are not yet clarified.
The improved deformability of uraemic erythrocytes
by the recombinant human erythropoietin therapy
was explained by the assumption that during recom-
binant human erythropoietin therapy an increasing
number of cells with normalized viscoelastic proper-
ties was formed due to stimulated erythropoiesis (13).
It is well known that the biochemical and biophysical
state of the cytoskeleton, which is attached to the
cytoplasmatic membrane surface, is of direct impor-
tance for the viscoelastic properties of the cell mem-
brane, and therefore determines the deformability of
the whole erythrocyte. It was mentioned above that
several authors have related the reduced deformability
of uraemic erythrocytes to a permanent oxidative
stress caused by so called uraemic toxins in the blood
plasma (7). If the impaired deformability is primarily
caused by the action of uraemic toxins, one would
expect that the erythrocytes formed under the recom-
binant human erythropoietin therapy would also pos-
sess this feature. But the findings of Meier et al. (13)
underline the fact that the impaired deformability of
erythrocytes from haemodialysed patients cannot be
attributed alone to an action of "uraemic toxins"
during ageing of erythrocytes in the blood circulation.
On the basis of the results presented here we propose
that the further increase of the intraerythrocytic con-
centrations of energy-rich adenosine nucleotides, es-
pecially ATP and AMP, within the younger cell frac-
tions, and ADP and AMP in the older cell fractions,
during recombinant human erythropoietin therapy, is
responsible for the improvement of rheological prop-
erties of the blood of patients with chronic renal
failure. Thus, the results of our study point to an
increase of haemocrit with an enhancement of the
proportion of younger erythrocytes, but not to an
improvement of the reduced life span of erythrocytes
of haemodialysis patients during recombinant human
erythropoietin therapy.
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